Skip to main content
Clinical Trials/NCT06268808
NCT06268808CompletedNot Applicable

Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in Italy

Abbott Diabetes Care16 sites in 1 country90 target enrollmentStarted: July 19, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
90
Locations
16
Primary Endpoint
HbA1c

Study Overview

Brief Summary

The goal of this clinical study is to determine the impact of starting the use of the FreeStyle Libre 2 glucose monitoring system, over a three month period, on HbA1c in adults with type 2 diabetes treated with a basal insulin regimen.

Detailed Description

This is a post-market, multi-centre, prospective, interventional single arm study in Italy.

Participants will use the FreeStyle Libre 2 Flash Glucose Monitoring System, according to the labelling, to monitor their glucose for approximately 3 months. Additional therapies may be introduced, if clinically indicated, based on review of the participant's clinical data and in line with national guidance.

HbA1c will be tested at the start and end of the study for primary endpoint analysis.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Aged ≥18 to ≤ 75 years.
  • Type 2 diabetes diagnosis ≥1 year prior to enrolment.
  • Type 2 diabetes treated with a basal insulin injection regimen with or without other antihyperglycaemic therapy at enrolment.
  • Current glucose lowering treatment regimen has been established for at least 3 months prior to enrolment.
  • Screening HbA1c ≥59 mmol/mol to ≤108 mmol/mol (≥7.5% and ≤12.0%, inclusive), within the last 60 days.

Exclusion Criteria

  • Participant is currently prescribed prandial or pre-mixed (biphasic) insulin at enrolment.
  • Currently participating in another study that could affect glucose measurements or glucose management.
  • Currently receiving dialysis treatment or receives dialysis during the study.
  • A female participant who is pregnant.
  • A breastfeeding female participant.

Arms & Interventions

Intervention

Other

FreeStyle Libre 2 Flash Glucose Monitoring System

Intervention: FreeStyle Libre 2 Flash Glucose Monitoring System (Device)

Outcomes

Primary Outcomes

HbA1c

Time Frame: 3 months

Change in HbA1c within group from baseline

Secondary Outcomes

  • Frequency of hypoglycaemia events(3 months)
  • Time below range (TBR)(3 months)
  • Time in range (TIR)(3 months)
  • Time above range (TAR)(3 months)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (16)

Loading locations...

Similar Trials